S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Forecast, Price & News

$1.72
+0.06 (+3.61%)
(As of 05/31/2023 ET)
Compare
Today's Range
$1.61
$1.81
50-Day Range
$0.31
$1.72
52-Week Range
$0.22
$9.11
Volume
836,262 shs
Average Volume
1.96 million shs
Market Capitalization
$14.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Virios Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Virios Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

925th out of 1,006 stocks

Pharmaceutical Preparations Industry

462nd out of 492 stocks


VIRI stock logo

About Virios Therapeutics (NASDAQ:VIRI) Stock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRI Stock News Headlines

VIRI: Ready to Move IMC-1 Into Phase 3 Program…
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
10-Q: VIRIOS THERAPEUTICS, INC.
Recap: Virios Therapeutics Q1 Earnings
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?
See More Headlines
Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRI Company Calendar

Last Earnings
3/14/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIRI
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-12,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.72 per share

Miscellaneous

Free Float
6,672,000
Market Cap
$14.33 million
Optionable
Not Optionable
Beta
2.05

Key Executives

  • Mr. Gregory Duncan (Age 57)
    Chairman & CEO
    Comp: $798.67k
  • Mr. Ralph D. Grosswald M.P.H. (Age 53)
    Sr. VP of Operations
    Comp: $274.69k
  • Dr. R. Michael Gendreau M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $459.9k
  • Ms. Angela Walsh (Age 55)
    CFO, SVP of Fin., Corp. Sec. & Treasurer
  • Ms. Carol Duffy Ph.D.
    Chief Scientific Advisor













VIRI Stock - Frequently Asked Questions

Should I buy or sell Virios Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Virios Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VIRI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIRI, but not buy additional shares or sell existing shares.
View VIRI analyst ratings
or view top-rated stocks.

How have VIRI shares performed in 2023?

Virios Therapeutics' stock was trading at $0.2360 at the beginning of 2023. Since then, VIRI shares have increased by 628.8% and is now trading at $1.72.
View the best growth stocks for 2023 here
.

Are investors shorting Virios Therapeutics?

Virios Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 327,500 shares, a decrease of 68.8% from the April 30th total of 1,050,000 shares. Based on an average daily volume of 2,790,000 shares, the days-to-cover ratio is presently 0.1 days.
View Virios Therapeutics' Short Interest
.

When is Virios Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VIRI earnings forecast
.

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings data on Tuesday, March, 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05.

When did Virios Therapeutics IPO?

(VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is Virios Therapeutics' stock symbol?

Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI."

Who are Virios Therapeutics' major shareholders?

Virios Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (1.94%) and Envestnet Asset Management Inc. (1.45%). Insiders that own company stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen.
View institutional ownership trends
.

How do I buy shares of Virios Therapeutics?

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Virios Therapeutics' stock price today?

One share of VIRI stock can currently be purchased for approximately $1.72.

How much money does Virios Therapeutics make?

Virios Therapeutics (NASDAQ:VIRI) has a market capitalization of $14.33 million. The company earns $-12,250,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How can I contact Virios Therapeutics?

The official website for the company is www.virios.com. The company can be reached via phone at 866-620-8655 or via email at ir@virios.com.

This page (NASDAQ:VIRI) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -